Add Yahoo as a preferred source to see more of our stories on Google. While it wasn’t long ago that Portsmouth Little Theatre announced the cast list for their next performance, “Darling, I’m Home,” ...

ATLANTA — Begrudgingly, Karl-Anthony Towns understands he may have to change aspects of his game as offensive fouls pile up amid the increasingly watchful eyes of the referees. “I’m going to keep ...

WATERBURY, CT. (WFSB) - Around 15 cars were involved in a massive pile up due to the weather in Waterbury Friday evening. Officials say that crews responded at around 7:32 p.m. to the area of Wall ...

Lockheed Martin continues to underperform, with a decade of low growth, margin pressure, and a lackluster trajectory. Recent White House scrutiny on defense contractor capital allocation threatens LMT ...

The only thing left for JJ Redick to do was joke about it. What else could be said after the Lakers made just six of 38 three-pointers in a 103-88 loss to the Clippers on Saturday? “I was proud that ...

Steve Bannon joined the ongoing dogpile on Ben Shapiro at Turning Point USA’s AmFest on Friday night. Shapiro spoke at the event on Thursday, where he ripped Candace Owens for peddling conspiracy ...

Freshmen Michael Nicosia and Gino Bozzi scored late to earn major decisions in the opening two bouts at 107 and 114 pounds, respectively. With the Golden Hawks’ win already secured, senior 285-pounder ...

2026 is shaping up to be a very expensive year. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. G.Skill has issued a statement directly ...

Snow has already pummeled parts of New York state, but even with snow on the ground, it's not too late to prepare for the pending wintry weather. Clearing your gutters and sealing up cracks can save ...

Gold-backed ETFs are again in focus as gold (or Au) continued its climb with a bullish trajectory towards a record high, with investors increasingly turning to such funds as a hedge against stock ...

After spending the year angling for a new approval in multiple sclerosis, Sanofi's stockings may hang empty this holiday season—at least when it comes to tolebrutinib in non-relapsing secondary ...